AFM13: a first-in-class tetravalent bispecific anti-CD30/CD16A antibody for NK cell-mediated immunotherapy

被引：0
|
作者：
Jingjing Wu
Jiaping Fu
Mingzhi Zhang
Delong Liu
机构：
[1] The First Affiliated Hospital of Zhengzhou University,Department of Oncology
[2] Shaoxing People’s Hospital,Department of Hematology
[3] New York Medical College,Division of Hematology & Oncology
来源：
Journal of Hematology & Oncology | / 8卷
关键词：
Maximum Tolerate Dose; Lenalidomide; Ibrutinib; Bispecific Antibody; Brentuximab Vedotin;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Monoclonal antibodies against CD20 molecule have been leading the revolution of lymphoma treatment. In addition to monoclonal antibodies against CD20 and CD30, novel agents of immunotherapeutics in clinical development are being developed and are rapidly migrating to clinical application. One area of active development is NK cell activators, such as AFM13. This review will highlight the latest development of AFM13 as the first-in-class tetravalent bispecific anti-CD30/CD16A antibody for NK cell-mediated immunotherapy.
引用
收藏
相关论文
共 50 条
  • [1] AFM13: a first-in-class tetravalent bispecific anti-CD30/CD16A antibody for NK cell-mediated immunotherapy
    Wu, Jingjing
    Fu, Jiaping
    Zhang, Mingzhi
    Liu, Delong
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2015, 8
  • [2] A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma
    Rothe, Achim
    Sasse, Stephanie
    Topp, Max S.
    Eichenauer, Dennis A.
    Hummel, Horst
    Reiners, Katrin S.
    Dietlein, Markus
    Kuhnert, Georg
    Kessler, Joerg
    Buerkle, Carolin
    Ravic, Miroslav
    Knackmuss, Stefan
    Marschner, Jens-Peter
    von Strandmann, Elke Pogge
    Borchmann, Peter
    Engert, Andreas
    BLOOD, 2015, 125 (26) : 4024 - 4031
  • [3] THE BISPECIFIC INNATE CELL ENGAGERS AFM13 (CD30/ CD16A) AND AFM24 (EGFR/CD16A) INCREASE THE FRACTION OF TUMOR TARGET-RESPONSIVE NK CELLS AND BOOST SERIAL KILLING
    Zambarda, Chiara
    Guldevall, Karolin
    Zambarda, Chiara
    Guldevall, Karolin
    Breunig, Christian
    Toullec, Damien
    Fontana, Jacopo
    Pinto, Sheena
    Pahl, Jens
    Wingert, Susanne
    Koch, Joachim
    Oenfelt, Bjorn
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A938 - A938
  • [4] A Phase I Study with the Bispecific Anti-CD30 x Anti-CD16A Antibody Construct AFM13 in Patients with Relapsed or Refractory Hodgkin Lymphoma
    Rothe, Achim
    Younes, Anas
    Reiners, Katrin S.
    Dietlein, Markus
    Eichenauer, Dennis A.
    Kessler, Joerg
    Topp, Max S.
    Hummel, Horst
    Ravic, Miroslav
    Hucke, Christian
    von Strandmann, Elke Pogge
    Engert, Andreas
    BLOOD, 2011, 118 (21) : 1585 - 1585
  • [5] A Phase I Study Of An Anti-CD30 x Anti-CD16A Bispecific Tandab Antibody, AFM13, In Patients With Relapsed Or Refractory Hodgkin Lymphoma
    Zhukovsky, Eugene
    Rothe, Achim
    von Tresckow, Bastian
    Topp, Max
    Younes, Anas
    Eichenauer, Dennis A.
    Hummel, Horst
    Reiners, Katrin S.
    Dietlein, Markus
    Kessler, Joerg
    Ravic, Miroslav
    Hucke, Christian
    Strandmann, Elke Poggevon
    Engert, Andreas
    BLOOD, 2013, 122 (21)
  • [6] Immune checkpoint inhibition by anti-PD-1 or CD137 co-stimulation enhances cytotoxicity towards CD30+ tumors mediated by the bispecific tetravalent CD30/CD16A TandAb AFM13
    Zhao, Xing
    Rajasekaran, Narendiran
    Reusch, Uwe
    Marschner, Jens-Peter
    Treder, Martin
    Kohrt, Holbrook E.
    CANCER RESEARCH, 2016, 76
  • [7] Anti-PD-1 to enhance NK-cell cytotoxicity towards CD30+Hodgkin lymphoma induced by CD30/CD16A TandAb AFM13
    Treder, Martin
    Zhao, Xing
    Rajasekaran, Narendiran
    Reusch, Uwe
    Marschner, Jens-Peter
    Kohrt, Holbrook Edwin
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [8] Cryopreserved CAR-like NK Cells Pre-Complexed with the CD30/CD16A Bispecific Innate Cell Engager (ICE®) AFM13 for the Treatment of CD30 + Malignancies
    Reusch, Uwe
    Ellwanger, Kristina
    Fucek, Ivica
    Mueller, Thomas
    Schniegler-Mattox, Ute
    Pahl, Jens
    Tesar, Michael
    Koch, Joachim
    BLOOD, 2021, 138
  • [9] Preclinical development of an anti-CD30/anti-CD16A bispecific tetravalent TandAb antibody for the treatment of Hodgkin lymphoma
    Knackmuss, Stefan H.
    Reusch, Uwe
    Burkhardt, Carmen
    Fucek, Ivica
    Le Gall, Fabrice
    Pauels, Hans-Gerd
    Zhukovsky, Eugene A.
    Little, Melvyn
    CANCER RESEARCH, 2012, 72
  • [10] AFM13, a novel bispecific (CD30xCD16A) tetravalent antibody (TandAb®) specifically engaging NK-cells to fight Hodgkin Lymphoma (HL)
    Marschner, J-P
    Treder, M.
    Kohrt, H. E.
    Topp, M. S.
    Engert, A.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 28 - 28
12345